Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

New strategies for treatment of inflammatory bowel disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Disease-Specific Enteric Microbiome Dysbiosis in Inflammatory Bowel Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neodymium-140 DOTA-LM3: Evaluation of anGenerator for PET with a Non-Internalizing Vector

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Targeting JAK-STAT signal transduction in IBD

    Research output: Contribution to journalReviewResearchpeer-review

  2. Role of Vitamin D in the Natural History of Inflammatory Bowel Disease

    Research output: Contribution to journalReviewResearchpeer-review

  3. Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Intestinal barrier integrity and inflammatory bowel disease: Stem cell-based approaches to regenerate the barrier

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

The etiology of inflammatory bowel disease (IBD), of which ulcerative colitis (UC) and Crohn's disease (CD) are the two most prevailing entities, is unknown. However, IBD is characterized by an imbalanced synthesis of pro-inflammatory mediators of the inflamed intestine, and for more than a decade tumor necrosis factor-(TNF) α has been a major target for monoclonal antibody therapy. However, TNF inhibitors are not useful for one third of all patients (i.e. "primary failures"), and further one third lose effect over time ("secondary failures"). Therefore, other strategies have in later years been developed including monoclonal antibodies targeting the interleukin (IL)-6 family of receptors (the p40 subunit of IL-12/IL-23) as well as monoclonal antibodies inhibiting adhesion molecules (the α4β7 heterodimers), which direct leukocytes to the intestinal mucosa. Recently, small molecules, which are inhibitors of Janus kinases (JAKs), hold promise with a tolerable safety profile and efficacy in UC, and the field of nanomedicine is emerging with siRNAs loaded into polyactide nanoparticles that may silence gene transcripts at sites of intestinal inflammation. Thus, drug development for IBD holds great promise, and patients as well as their treating physicians can be hopeful for the future.

Original languageEnglish
JournalFrontiers in Medicine
Volume1
Pages (from-to)12-17
Number of pages6
DOIs
Publication statusPublished - 2014

ID: 44871543